Clinical Trials Browser

Phase 2 × Interventional × brostallicin × Clear all

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00041249 2012-07-18

Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase 2 Completed

64 enrolled

GastrointestinalSarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous

NCT00633165 2010-02-26

SMI-BRS-202

Phase 2 Unknown

24 enrolled

Sarcoma

Sarcoma, Liposarcoma, Myxoid

Clinical Trials

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

SMI-BRS-202